{'fraction_non_alphanumeric': 0.020093770931011386, 'fraction_numerical': 0.0053583389149363695, 'mean_word_length': 5.916666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Research of interactions in the dopamine-serotonin-somatostatin system promises new outlook in fundamental and practical respects].

Dopamine and serotonin are the two important key neurotransmitters, which participate in the formation and regulation of various physiological parameters in the normal and pathological states. It is very interesting and important in both fundamental and practical respect to analyze interactions of dopamine and serotonin with somatostatin--a peptide hormone suppressing the secretion of many other regulatory peptides and various bioactive substances. In the present work, a huge amount of experimental data on the interactions of dopamine and serotonin with somatostatin was collected and analyzed. Literature sources mainly cover the period of 1970 - 2006. Compilation of an information database on dopamine/serotonin--somatostatin interactions has been the next stage. Analysis of the effects of dopamine and somatostatin revealed unilateral influence of these endogenous regulators and also of the induced and/or inhibited peptides on the level of depression, stress, food intake, angiogenesis and cancerogenesis, thus making it possible to increase and prolong their effects via cascade mechanisms. Potentially possible combinations of somatostatin and dopamine analogs, and chimeric somatostatin/dopamine molecules are proposed for the treatment and correction of different pathological states, including acromegaly, prolactinemia, and hyperinsulinism.